Insulin Market To Reach USD 28 Billion By 2032, Reports 2.4% CAGR

Overview

New York, NY – April 24, 2025 – Global Insulin market size is expected to be worth around USD 28 Billion by 2032 from USD 23 Billion in 2023, growing at a CAGR of 2.4% during the forecast period from 2023 to 2032

Insulin is a vital hormone produced by the pancreas that regulates blood glucose levels by facilitating the uptake of glucose into cells for energy or storage. It plays a crucial role in carbohydrate, fat, and protein metabolism. In individuals with diabetes mellitus, insulin production is impaired (Type 1 diabetes) or the body becomes resistant to insulin’s effects (Type 2 diabetes), necessitating external insulin therapy to maintain normal blood sugar levels.

Since its discovery in 1921, insulin therapy has remained the cornerstone of diabetes management. It is commonly administered via subcutaneous injections or insulin pumps. The development of different types of insulin including rapid-acting, short-acting, intermediate-acting, and long-acting formulations—has enhanced treatment flexibility and glycemic control.

Globally, over 537 million people are living with diabetes, as per the International Diabetes Federation, and this number is expected to rise significantly. Insulin access is essential to prevent complications such as kidney failure, blindness, and cardiovascular diseases. Efforts by global health organizations aim to improve insulin affordability and availability, particularly in low- and middle-income countries. Advancements in biosynthetic insulin production and digital delivery systems continue to improve patient outcomes and quality of life, making insulin an enduring focus in global healthcare strategies.

Key Takeaways

• Market Size: The global insulin market is projected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2032, indicating sustained demand driven by rising diabetes prevalence.
• Market Trends: The use of insulin has seen a significant increase, attributed to the rising incidence of diabetes worldwide and growing awareness regarding its effective management.
• Product Analysis: Among product types, long-acting insulin dominates the market, accounting for approximately 49% of the total market share, due to its prolonged therapeutic effect and reduced dosing frequency.
• Type Analysis: The insulin analog segment leads the market, holding a commanding 84% market share. These analogs are engineered to replicate the body’s natural insulin release patterns more accurately than conventional insulins.
• Application Analysis: Type 1 Diabetes Mellitus (T1DM) remains the leading application segment, comprising 75% of the market share, reflecting the lifelong dependency of T1DM patients on insulin therapy.
• Distribution Channel Analysis: Retail pharmacies serve as the primary distribution channel, capturing 48% of the market share, owing to their widespread accessibility and regular patient interaction.
• Market Drivers: Key growth drivers include the increasing global prevalence of diabetes and a heightened focus on comprehensive healthcare management.
• Market Restraints: The market is constrained by high insulin costs and the requirement for precise dosing, which may hinder widespread adoption, particularly in low-resource settings.
• Opportunities: Future growth is expected to be fueled by advancements in insulin delivery technologies and ongoing research into next-generation insulin formulations.
• Market Challenges: The market faces challenges including stringent regulatory standards, intensifying competition, and limited insulin accessibility in low- and middle-income countries.
• Regional Insights: North America is anticipated to maintain market leadership, with a projected share of 38.2% by 2022, primarily due to the region’s high diabetes burden and robust healthcare infrastructure.

US Tariff Impact on Insulin Market

• Increased Costs for Insulin Delivery Devices: While insulin itself has not been directly subjected to tariffs, related medical devices such as insulin pumps and continuous glucose monitors (CGMs) are affected. For instance, devices manufactured by companies like Medtronic and Abbott, which have production facilities in Ireland, may face tariffs up to 20% when imported into the U.S. These additional costs are likely to be passed on to consumers, potentially increasing the financial burden on patients requiring these essential devices.
• Potential Disruption in Generic Insulin Supply: The U.S. heavily relies on imported generic drugs, with India being a significant supplier. Tariffs on pharmaceutical imports could lead to increased production costs for these generics, making them less profitable. Consequently, manufacturers might reduce or cease production, leading to shortages. Given that generics account for 90% of the U.S. drug supply, such disruptions could have widespread implications.
• Shift in Manufacturing Investments: In anticipation of potential tariffs, several pharmaceutical companies are increasing their investments in U.S.-based manufacturing. For example, Roche announced a $50 billion investment over the next five years to expand its U.S. facilities, aiming to create over 12,000 jobs. Similarly, Eli Lilly plans to invest at least $27 billion in new U.S. plants. These moves are strategic efforts to mitigate the impact of tariffs and ensure continued access to the U.S. market
• Potential Price Increases for Consumers: If tariffs are imposed on insulin or its components, the increased costs could be transferred to consumers. This scenario is particularly concerning given that the U.S. already has higher insulin prices compared to other countries. For instance, in 2018, the U.S. manufacturer prices for insulin were, on average, 8.1 times higher than those in 32 non-U.S. countries.

Insulin Statistics

• Ultra-rapid acting insulin has an onset of 2 to 15 minutes, peaks between 30 to 60 minutes, and lasts for 4 hours. It is typically taken with the first bite of a meal and is often used in conjunction with long-acting insulin.
• Rapid-acting insulin takes effect within 15 minutes, reaches its peak at about 1 hour, and has a duration of 2 to 4 hours. This type of insulin is usually administered right before a meal and is frequently used alongside longer-acting insulin.
• Rapid-acting inhaled insulin begins to work within 10 to 15 minutes, peaks at 30 minutes, and continues to be effective for 3 hours. It is commonly taken just before a meal and is used with injectable long-acting insulin.
• Regular or short-acting insulin has an onset of 30 minutes, peaks between 2 to 3 hours, and lasts from 3 to 6 hours. This insulin is typically taken 30 to 60 minutes before eating.
• Intermediate-acting insulin starts to work 2 to 4 hours after injection, peaks from 4 to 12 hours, and maintains its effect for 12 to 18 hours. It is usually administered once or twice daily to cover insulin needs for half a day or overnight.
• Long-acting insulin begins to act 2 hours post-administration and does not exhibit a peak. Its effects last up to 24 hours and it is taken once daily. This insulin can also be combined with rapid- or short-acting insulin as needed.
• Ultra-long acting insulin takes about 6 hours to start working, does not peak, and its effects last for 36 hours or more. Like long-acting insulin, it is taken once a day and can be used with faster-acting insulin types if required.
• Premixed insulin varies in its onset from 5 to 60 minutes, has varied peaks, and a duration of 10 to 16 hours. It is typically administered twice daily, often 10 to 30 minutes before breakfast and dinner.

Segmentation Analysis

• Product Type Analysis: Long-acting insulin holds a dominant 49% market share. It maintains steady insulin levels for 24 hours or more, offering vital control for both Type 1 and Type 2 diabetics. This reduces blood sugar fluctuations and diabetic complications. The once-daily dosage enhances patient convenience. Meanwhile, biosimilar insulin is projected to grow due to its proven safety and efficacy. Clinical trials ensure biosimilars match reference products in structure and performance, supporting broader access to affordable insulin therapy.
• Type Analysis: Analog insulin accounts for 84% of the market. These synthetic versions closely mimic natural human insulin, offering controlled absorption and fewer hypoglycemia incidents. Minor changes in amino acid sequences improve pharmacokinetics, making analogs more effective than traditional insulins. While analogs offer clinical benefits, their higher costs and limited insurance coverage can be barriers. Nevertheless, their demand continues to grow due to better patient outcomes and increasing adoption across diabetes care settings.
• Application Analysis: Type 1 Diabetes Mellitus (T1DM) drives 75% of insulin use globally. T1DM is an autoimmune condition that destroys pancreatic insulin-producing cells, requiring lifelong insulin therapy. Without it, blood glucose rises dangerously, causing serious complications. As T1DM cases rise and more Type 2 Diabetes Mellitus (T2DM) patients begin insulin therapy, demand increases. Insulin is vital for T2DM to manage blood sugar and prevent complications such as kidney failure, vision loss, and cardiovascular disease.
• Distribution Channel Analysis: Retail pharmacies dominate insulin distribution with a 48% market share. These include drugstores, supermarkets, and independent outlets. They source insulin from manufacturers and wholesalers, offering convenient access to essential medications. Extended operating hours and widespread availability make retail pharmacies the most preferred channel for insulin purchases. Their accessibility enhances patient adherence to insulin therapy, especially in urban and semi-urban regions where healthcare facility visits may be limited.

Market Segments

Based on Product Type

• Rapid-Acting Insulin
• Long-Acting Insulin
• Combination Insulin
• Biosimilar
• Other Products

Based on Type

• Human Insulin
• Insulin Analog

Based on Application

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Based on Distribution Channel

• Hospitals
• Retail Pharmacies
• Other Distribution Channel

Regional Analysis

North America is projected to remain the most lucrative region in the global insulin market, accounting for the largest market share of approximately 38%. This dominance can be attributed to the high prevalence of diabetes, the presence of key market players, and supportive government initiatives aimed at enhancing diabetes management and access to treatment.

Conversely, the Asia-Pacific region is expected to exhibit the fastest growth rate during the forecast period. This growth is driven by the rising incidence of diabetes, ongoing improvements in healthcare infrastructure, and increasing disposable income, which collectively enhance access to insulin therapies across emerging economies in the region.

Emerging Trends

• Once-Weekly Insulin Formulations: Recent advancements have led to the development of once-weekly insulin analogs, such as insulin icodec and insulin efsitora alfa. These formulations aim to reduce the frequency of injections for patients, potentially improving adherence and glycemic control. Clinical trials have demonstrated that insulin icodec has a plasma half-life exceeding eight days, allowing for weekly dosing schedules.
• Smart Insulin Technologies: Innovations in glucose-responsive insulin (GRI) are progressing, with compounds like NNC2215 designed to activate in response to elevated blood glucose levels and deactivate as levels normalize. This mechanism aims to mimic the body’s natural insulin response, reducing the risk of hypoglycemia.
• Artificial Pancreas Systems: The integration of continuous glucose monitoring with automated insulin delivery systems, known as hybrid closed-loop systems or artificial pancreas devices, is becoming more prevalent. These systems automatically adjust insulin delivery based on real-time glucose readings, enhancing glycemic control and reducing patient burden.
• Oral Insulin Development: Research into oral insulin formulations, such as insulin tregopil and ORMD-0801, is ongoing. These oral agents aim to provide a non-invasive alternative to injections, potentially improving patient compliance and quality of life.
• Cost Reduction Initiatives: Efforts to make insulin more affordable have led to significant price reductions. For instance, the average price per insulin unit in the U.S. decreased by 42%, from $0.33 in 2019 to $0.19 in mid-2024.

Use Cases

Management of Type 1 Diabetes: Insulin therapy remains essential for individuals with type 1 diabetes, as their bodies produce little to no insulin. In the United States, approximately 304,000 youths under 20 years have type 1 diabetes, necessitating regular insulin administration.

Treatment of Type 2 Diabetes: While lifestyle modifications and oral medications are first-line treatments for type 2 diabetes, insulin therapy becomes necessary as the disease progresses. In 2024, the global prevalence of diabetes reached approximately 589 million adults, highlighting the extensive need for effective insulin therapies.

Hospital and Emergency Care: In acute care settings, insulin is used to manage hyperglycemia in hospitalized patients, including those without a prior diabetes diagnosis. Effective glycemic control in hospitals is associated with improved patient outcomes and reduced complications.

Gestational Diabetes Management: Pregnant women with gestational diabetes may require insulin therapy to maintain optimal blood glucose levels, ensuring the health of both mother and fetus. Insulin does not cross the placenta, making it a safe option during pregnancy.

Use in Insulin Pumps and Pens: Advancements in insulin delivery devices, such as insulin pumps and smart pens, have improved the precision and convenience of insulin administration. These devices allow for more accurate dosing and better integration with glucose monitoring systems.

Conclusion

In conclusion, the global insulin market continues to demonstrate robust growth, driven by the rising prevalence of diabetes and advancements in insulin therapies and delivery technologies. Long-acting and analog insulins dominate due to their clinical efficacy and patient-friendly profiles. North America leads the market, while Asia-Pacific shows strong future growth potential.

Innovations such as once-weekly insulins, smart delivery systems, and oral formulations are improving patient adherence and outcomes. Despite challenges like cost and accessibility, ongoing research, government support, and global health initiatives are enhancing insulin availability, solidifying its role as a cornerstone in diabetes care worldwide.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF